Semax

About Semax

Semax is a synthetic heptapeptide (MEHFPGP) that researchers developed from ACTH 4-10. They've enhanced its stability through Pro-Gly-Pro modification, making it more robust for laboratory work. This nootropic research compound works by modulating neurotrophin expression — particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — whilst also influencing dopaminergic and serotonergic neurotransmitter systems. Laboratory studies show it's got some impressive neuroprotective properties. It activates TrkB receptors and enhances synaptic plasticity mechanisms, which is exactly what you'd want to see in this type of compound. Researchers are using it across various applications: cognitive enhancement studies, neurodegeneration models, and stress response investigations. The Russian clinical research has turned up some particularly interesting findings. They've documented improved memory consolidation and learning capacity in laboratory models, with effects showing up within 24-48 hours of administration. What's quite clever about Semax is its unique selectivity for cognitive pathways — it doesn't produce significant peripheral ACTH activity, which keeps things clean for research purposes. Our pharmaceutical-grade preparation comes as a lyophilised white powder with >98% purity, verified by HPLC analysis. Each vial contains precisely measured quantities that are perfect for controlled research protocols. You'll need to store it at -20°C to maintain peptide integrity — that's crucial for getting consistent results. We include reconstitution protocols and handling guidelines with each order, so you'll have everything you need for optimal research outcomes.

Research Applications

• Investigated for modulation of BDNF and NGF expression in neuronal cell models
• Studied for influence on dopaminergic and serotonergic neurotransmission pathways
• Researched for neuroprotective signalling under ischaemic-injury models in vitro
• Associated with regulation of immediate-early gene expression in cortical tissue studies
• Investigated as a model compound for melanocortin and ACTH-fragment receptor research
• Studied for effects on attention- and memory-related biomarkers in preclinical models

Research Mechanism — Semax

A simplified summary of what Semax is studied for in research models. For laboratory in-vitro use only.

1. 1

   Molecular target

   Semax has been investigated as a modulator of central neurotrophin signalling and monoaminergic tone. Binding studies describe interactions with melanocortin receptors and regulation of BDNF/NGF transcription.

   • Studied for upregulation of BDNF and NGF mRNA
   • Investigated affinity at MC4-R melanocortin receptors
   • Probed effects on dopaminergic and serotonergic transporters
2. 2

   Investigated pathways

   Preclinical literature characterises Semax across neurotrophic, anti-oxidative, and HPA-axis associated signalling cascades. Effects on enkephalin degradation have also been reported.

   • TrkA/TrkB receptor downstream signalling cascades
   • Inhibition of enkephalin-degrading enzymes in CNS tissue
   • Modulation of HIF-1α under hypoxic research models
3. 3

   Preclinical research applications

   Used in rodent and in vitro studies of cognition-related endpoints, ischaemic injury models, and neurotrophic gene expression. Not approved for human use.

   • Rodent maze and attention paradigm research
   • Middle cerebral artery occlusion (MCAO) preclinical models
   • In vitro neuronal culture neurotrophin expression assays

For research use only. Semax is not approved as a medicine in the UK and is not intended for human or veterinary administration. See the compliance page for full terms.